{"component": "definition", "props": {"groups": [{"snippet_links": [], "size": 60, "snippet": "means the taking of two or more ingredients and fabricating them into a single", "samples": [{"hash": "kD8m6W1FHt8", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?991+ful+HB1819H1+pdf", "label": "legacylis.virginia.gov", "score": 18.2345180511, "published": false}, {"hash": "jqqYLpueQSd", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?961+ful+SB34S1+pdf", "label": "legacylis.virginia.gov", "score": 18.2345180511, "published": false}, {"hash": "6Vhqizlt3Rl", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?971+ful+SB1190+pdf", "label": "legacylis.virginia.gov", "score": 17.9384098053, "published": false}], "hash": "d766edd2e64f87fbb539a6e972bac962", "id": 1}, {"snippet_links": [{"key": "medically-necessary", "type": "clause", "offset": [26, 45]}, {"key": "according-to", "type": "definition", "offset": [126, 138]}, {"key": "an-individual", "type": "clause", "offset": [176, 189]}], "size": 46, "snippet": "means to form or create a Medically Necessary customized composite product by combining two (2) or more different ingredients according to a Physician\u2019s specifications to meet an individual patient\u2019s need.", "samples": [{"hash": "3VqkNTldWRC", "uri": "/contracts/3VqkNTldWRC#compound", "label": "Agreement of Coverage", "score": 28.1062068939, "published": true}, {"hash": "aAHZnN98OfW", "uri": "/contracts/aAHZnN98OfW#compound", "label": "Epo Agreement of Coverage", "score": 26.835729599, "published": true}, {"hash": "2nipX0p8ghd", "uri": "/contracts/2nipX0p8ghd#compound", "label": "Agreement of Coverage", "score": 26.835729599, "published": true}], "hash": "40ff46fceb03b8fd2f070b4666bc9211", "id": 2}, {"snippet_links": [], "size": 33, "snippet": "means [***].", "samples": [{"hash": "9uAozd7afCt", "uri": "/contracts/9uAozd7afCt#compound", "label": "Research Collaboration Agreement (ArriVent BioPharma, Inc.)", "score": 35.86926651, "published": true}, {"hash": "bLQKtSbDx2T", "uri": "/contracts/bLQKtSbDx2T#compound", "label": "Research Collaboration Agreement (ArriVent Biopharma, Inc.)", "score": 35.0095825195, "published": true}, {"hash": "cqepFxHXj6a", "uri": "/contracts/cqepFxHXj6a#compound", "label": "Research Collaboration Agreement (ArriVent Biopharma, Inc.)", "score": 34.9274482727, "published": true}], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 3}, {"snippet_links": [{"key": "appendix-1", "type": "clause", "offset": [255, 265]}, {"key": "by-pfizer", "type": "clause", "offset": [309, 318]}, {"key": "for-clarity", "type": "clause", "offset": [335, 346]}, {"key": "not-limited", "type": "clause", "offset": [555, 566]}], "size": 29, "snippet": "means (1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin- 3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3- azabicyclo[3.1.0]hexane-2-carboxamide, which has the molecular formula C23H32F3N5O4 and having the structure to be set forth on Appendix 1 attached hereto, as referred to internally by Pfizer as PF-07321332. For clarity, \u201cCompound\u201d includes all forms of (1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2- oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]- 3-azabicyclo[3.1.0]hexane-2-carboxamide, including but not limited to, isomers, stereoisomers, diastereomers, tautomers, hydrates, solvates, crystal forms including crystalline forms and co-crystalline forms, amorphous forms, polymorphs, metabolites and prodrugs thereof. Additionally, \u201cCompound\u201d includes all deuterated forms.", "samples": [{"hash": "9UKSM6MoXOX", "uri": "/contracts/9UKSM6MoXOX#compound", "label": "License Agreement", "score": 33.493347168, "published": true}, {"hash": "8BTiZcAhKvm", "uri": "/contracts/8BTiZcAhKvm#compound", "label": "License Agreement", "score": 33.2059211731, "published": true}, {"hash": "gi8YtayxFOM", "uri": "/contracts/gi8YtayxFOM#compound", "label": "License Agreement", "score": 33.1758117676, "published": true}], "hash": "4dbac8283618729900792cd4e1086f04", "id": 4}, {"snippet_links": [{"key": "pursuant-to", "type": "definition", "offset": [61, 72]}, {"key": "in-anticipation-of", "type": "definition", "offset": [76, 94]}, {"key": "prescription-drug-order", "type": "definition", "offset": [103, 126]}, {"key": "not-limited", "type": "clause", "offset": [142, 153]}, {"key": "intravenous-admixture", "type": "definition", "offset": [169, 190]}, {"key": "this-chapter", "type": "definition", "offset": [260, 272]}, {"key": "modification-of", "type": "clause", "offset": [327, 342]}, {"key": "drug-products", "type": "definition", "offset": [343, 356]}, {"key": "prior-to", "type": "definition", "offset": [357, 365]}], "size": 28, "snippet": "or \"compounding\" means the preparation or labeling of a drug pursuant to or in anticipation of a valid prescription drug order including, but not limited to, packaging, intravenous admixture or manual combination of drug ingredients. \"Compounding,\" as used in this chapter, shall not preclude simple reconstitution, mixing, or modification of drug products prior to administration by nonpharmacists;", "samples": [{"hash": "cR9lvBBAGKI", "uri": "/contracts/cR9lvBBAGKI#compound", "label": "Definitions for Chapter", "score": 26.699508667, "published": true}, {"hash": "J29hC99fb5", "uri": "/contracts/J29hC99fb5#compound", "label": "Definitions for Chapter", "score": 17.5057029724, "published": true}, {"hash": "aBuTk24L1u8", "uri": "https://apps.legislature.ky.gov/record/09RS/hb297/bill.doc", "label": "apps.legislature.ky.gov", "score": 8.4483232498, "published": false}], "hash": "be5fd7828e39c8dcab9127f0cc97cce3", "id": 5}, {"snippet_links": [], "size": 13, "snippet": "or \"compounding\" means the preparation or labeling of a drug", "samples": [{"hash": "ef5Slpx7vwc", "uri": "https://apps.legislature.ky.gov/recorddocuments/bill/24RS/sb27/bill.pdf", "label": "apps.legislature.ky.gov", "score": 15.9122858047, "published": false}, {"hash": "5Xi2k3l6Hq2", "uri": "https://apps.legislature.ky.gov/recorddocuments/bill/24RS/SB27/SCS1.pdf", "label": "apps.legislature.ky.gov", "score": 15.84416008, "published": false}, {"hash": "dYSREQ06GZt", "uri": "https://apps.legislature.ky.gov/recorddocuments/bill/24RS/hb806/orig_bill.pdf", "label": "apps.legislature.ky.gov", "score": 15.7817811966, "published": false}], "hash": "1a280d0e87014e448f0a070aed9ce4af", "id": 6}, {"snippet_links": [{"key": "dosage-form", "type": "definition", "offset": [117, 128]}], "size": 12, "snippet": "means the taking of two or more ingredients and fabricating them into a single preparation, usually referred to as a dosage form.", "samples": [{"hash": "gtDGZyY9a53", "uri": "https://lis.virginia.gov/cgi-bin/legp604.exe?961+ful+CHAP0152+pdf", "label": "lis.virginia.gov", "score": 11.308008194, "published": false}, {"hash": "bpZ2dOcMBF6", "uri": "https://lis.virginia.gov/cgi-bin/legp604.exe?031+ful+CHAP0509+pdf", "label": "lis.virginia.gov", "score": 11.2819986343, "published": false}, {"hash": "9FTMrobfd1B", "uri": "https://lis.virginia.gov/cgi-bin/legp604.exe?031+ful+CHAP0995+pdf", "label": "lis.virginia.gov", "score": 11.2121829987, "published": false}], "hash": "cfd8f7c9a8f568046fcbed5750546a87", "id": 7}, {"snippet_links": [{"key": "defined-above", "type": "clause", "offset": [3, 16]}, {"key": "the-recitals", "type": "clause", "offset": [20, 32]}], "size": 11, "snippet": "is defined above in the Recitals.", "samples": [{"hash": "hNHKIxYRP10", "uri": "/contracts/hNHKIxYRP10#compound", "label": "License Agreement (CPEX Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "f9b7dvoFxy9", "uri": "/contracts/f9b7dvoFxy9#compound", "label": "License Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "eb5fv4w3rv6", "uri": "/contracts/eb5fv4w3rv6#compound", "label": "License Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}], "hash": "101eb9d13dc646a90ee1d04a2b0f62fa", "id": 8}, {"snippet_links": [{"key": "chemical-compound", "type": "definition", "offset": [8, 25]}, {"key": "by-or-under-the-direction-of", "type": "definition", "offset": [100, 128]}, {"key": "term-of-the-research-program", "type": "clause", "offset": [165, 193]}, {"key": "this-agreement", "type": "clause", "offset": [200, 214]}, {"key": "the-original-agreement", "type": "clause", "offset": [319, 341]}], "size": 11, "snippet": "means a chemical compound, including salts and prodrugs thereof, which is synthesized and/or tested by or under the direction of VERTEX or its Affiliates during the term of the Research Program under this Agreement, or which was synthesized and/or tested by and/or under the direction of Aurora or its Affiliates under the Original Agreement; which is either a Potentiator or a Corrector, or both; and which [***]", "samples": [{"hash": "68S373CJgzz", "uri": "/contracts/68S373CJgzz#compound", "label": "Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 32.8384666443, "published": true}, {"hash": "jIVDMjaL1N", "uri": "/contracts/jIVDMjaL1N#compound", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7816562653, "published": true}, {"hash": "aHrGezSDAKR", "uri": "/contracts/aHrGezSDAKR#compound", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7433261871, "published": true}], "hash": "3b5203ab7da9bc12d294070158b7f97b", "id": 9}, {"snippet_links": [{"key": "for-the-purpose-of", "type": "definition", "offset": [69, 87]}], "size": 11, "snippet": "means to mix, combine or put together vari- ous ingredients or drugs for the purpose of dispensing.", "samples": [{"hash": "lygC3wnBpfq", "uri": "https://docs.legis.wisconsin.gov/statutes/statutes/450.pdf", "label": "docs.legis.wisconsin.gov", "score": 9.5065021515, "published": false}, {"hash": "gmdGCKTXWlS", "uri": "https://docs.legis.wisconsin.gov/2017/statutes/statutes/450.pdf", "label": "docs.legis.wisconsin.gov", "score": 7.6557154655, "published": false}, {"hash": "bhZBPQL9xR1", "uri": "https://docs.legis.wisconsin.gov/2015/statutes/statutes/450.pdf", "label": "docs.legis.wisconsin.gov", "score": 5.5044488907, "published": false}], "hash": "0489377a6f28727d9130fafeebc693ed", "id": 10}], "next_curs": "ClUST2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIRY29tcG91bmQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"size": 2964, "snippet": "means the taking of two or more ingredients and fabricating them into a single", "title": "Compound", "id": "compound", "examples": ["Subject to the terms and conditions of this Agreement, Sermonix hereby grants to \u2587\u2587\u2587\u2587\u2587\u2587 an exclusive (even as to Sermonix and its Affiliates), royalty-bearing license, with the right to grant sublicenses through multiple tiers in accordance with Section 2.2, under the Licensed Technology, to Develop, Manufacture and have Manufactured, Commercialize and otherwise Exploit the Licensed <strong>Compound</strong> and Licensed Products in the Field in the Territory.", "If any Party or its Affiliates or (sub)licensees becomes the subject of a Third Party\u2019s claim or assertion that the Exploitation of the Licensed <strong>Compound</strong> or any Licensed Product infringes one or more Patents of such Third Party (each, a \u201cThird Party Infringement Claim\u201d), the Party first becoming aware of the Third Party Infringement Claim will promptly notify the other Party in writing.", "As between the Parties, \u2587\u2587\u2587\u2587\u2587\u2587 shall (itself or through its Affiliates or Sublicensees) have the sole right, at its sole cost and expense, to conduct all Development of the Licensed <strong>Compound</strong> and Licensed Products in the Field in the Territory, and \u2587\u2587\u2587\u2587\u2587\u2587 shall use Commercially Reasonable Efforts to Develop at least one Licensed Product in the Field in the Territory.", "Upon \u2587\u2587\u2587\u2587\u2587\u2587\u2019s request, [***] Sermonix shall transfer Manufacturing-related records and data and provide Athira with reasonable technical assistance to enable Athira or its designated Third Party contract manufacturer to Manufacture the Licensed <strong>Compound</strong> and Licensed Products in the Territory (the \u201cManufacturing Technology Transfer\u201d).", "In addition, upon \u2587\u2587\u2587\u2587\u2587\u2587\u2019s reasonable written request, \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 shall participate in (or, if requested by \u2587\u2587\u2587\u2587\u2587\u2587, attend as an observer) any meeting with a Regulatory Authority in the Territory relating to the Licensed <strong>Compound</strong> or any Licensed Product.", "For clarity, the license granted to \u2587\u2587\u2587\u2587\u2587\u2587 under this Section 2.1 shall not include rights to Exploit any active pharmaceutical ingredient that is proprietary to Sermonix and is not the Licensed <strong>Compound</strong>.", "All Regulatory Materials relating to the Licensed <strong>Compound</strong> or any Licensed Product with respect to the Territory shall, as between the Parties, be owned by and the sole property of \u2587\u2587\u2587\u2587\u2587\u2587, and shall be held in the name of \u2587\u2587\u2587\u2587\u2587\u2587 or its Affiliate, Sublicensee or designee.", "Effective as of the Effective Date, Sermonix hereby transfers title to Sermonix\u2019s existing inventory of drug substance and drug product for the Licensed <strong>Compound</strong> and Licensed Products to \u2587\u2587\u2587\u2587\u2587\u2587 (\u201cExisting Inventory\u201d), which is currently held by [***] at one or more of its facilities pursuant to the [***] Agreement or by [***] at one or more of its facilities pursuant to the [***] Agreement.", "Following the transfer of such inventory and [***], \u2587\u2587\u2587\u2587\u2587\u2587 shall [***] responsibility [***] for supplying drug substance and drug product for the Licensed <strong>Compound</strong> and the Licensed Products to Henlius [***] for \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2019s conduct of the \u2587\u2587\u2587\u2587\u2587\u2587 3 Study in the Retained Territory and \u2587\u2587\u2587\u2587\u2587\u2587 may retain all amounts received from Henlius with respect to such supply.", "As between the Parties, Sermonix shall (itself or through its Affiliates or Ex-Territory Licensee(s)) have the sole right and responsibility, at its sole cost and expense, to conduct all Development of the Licensed <strong>Compound</strong> and Licensed Products in the Field in the Retained Territory."], "related": [["licensed-compound", "Licensed Compound", "Licensed <strong>Compound</strong>"], ["collaboration-compound", "Collaboration Compound", "Collaboration <strong>Compound</strong>"], ["lead-compound", "Lead Compound", "Lead <strong>Compound</strong>"], ["compounds", "Compounds", "<strong>Compounds</strong>"], ["licensed-compounds", "Licensed Compounds", "Licensed <strong>Compounds</strong>"]], "related_snippets": [], "updated": "2026-04-09T06:48:03+00:00"}, "json": true, "cursor": ""}}